Anuo Pharmaceuticals: Has signed a securities purchase agreement for the company's private equity financing (PIPE), with an estimated total financing amount of approximately $140 million.

2026-02-14 01:15:48

Abstract generation in progress

Recently, Anno Pharmaceuticals announced that it has signed a securities purchase agreement for a private placement of equity (PIPE) with a listed company, with an expected total financing amount of approximately $140 million (before deducting placement agent and other related fees).

In this private placement, the company will issue 64,615,386 Class A common shares to investors at a price of $2.1667 per share (equivalent to $6.50 per American Depositary Share (ADS)), with each ADS representing three Class A common shares.

The financing is led jointly by Cormorant Asset Management and Columbia Threadneedle Investments, and includes other new and existing investors such as Balyasny Asset Management L.P., Point72, Squadron Capital Management, and Casdin Capital. Additionally, approximately $55 million worth of shares will be sold to entities controlled by the company’s Chairman and CEO, Yu Yang.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.